Tropisetron

Identification

Name
Tropisetron
Accession Number
DB11699
Description

Tropisetron is an indole derivative with antiemetic activity. As a selective serotonin receptor antagonist, tropisetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy-and radiotherapy-induced nausea and vomiting.

Tropisetron appears to be well tolerated with the most frequently reported adverse effect being headache. Extrapyramidal side effects are rare upon using tropisetron.

Type
Small Molecule
Groups
Approved, Investigational
Structure
Thumb
Weight
Average: 284.3529
Monoisotopic: 284.152477894
Chemical Formula
C17H20N2O2
Synonyms
  • Tropisetron

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication

For the prevention of nausea and vomiting induced by cytotoxic therapy and postoperative.

Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics
Not Available
Mechanism of action

Tropisetron competitively binds to and blocks the action of serotonin at 5HT3 receptors peripherally on vagus nerve terminals located in the gastrointestinal (GI) tract as well as centrally in the chemoreceptor trigger zone (CTZ) of the area postrema of the central nervous system (CNS). This results in the suppression of chemotherapy- and radiotherapy-induced nausea and vomiting.

TargetActionsOrganism
A5-hydroxytryptamine receptor 3A
antagonist
Humans
Absorption

The absorption of tropisetron from the gastrointestinal tract is rapid (mean half-life of about 20 minutes) and nearly complete (more than 95%). Due to first-pass metabolism in the liver, the absolute bioavailability of a 5 mg oral dose is 60%. The peak plasma concentration is attained within three hours.

Volume of distribution

400-600 L.

Protein binding

71% bound to plasma protein in a non-specific manner.

Metabolism

The metabolism of tropisetron occurs by hydroxylation at the 5, 6 or 7 positions of its indole ring, followed by a conjugation reaction to the glucuronide or sulphate with excretion in the urine or bile (urine to faeces ratio 5:1). The metabolites have a greatly reduced potency for the 5-HT3 receptor and do not contribute to the pharmacological action of the drug.

Route of elimination

About 8% of tropisetron is excreted in the urine as unchanged drug, 70% as metabolites; 15% is excreted in the feces.

Half-life

5.7 h.

Clearance

1800 ml/min.

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

LD50: 265 mg/kg (Rat, oral).

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2D6CYP2D6*1XNNot AvailableNormal allele duplicated.ADR InferredUltra-rapid drug metabolizer. Risk of toxicity, alternative drug recommended.Details
Cytochrome P450 2D6CYP2D6*2XNNot Available2850C>T / 4180G>C  … show all ADR InferredUltra-rapid drug metabolizer. Risk of toxicity, alternative drug recommended.Details

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirAbacavir may decrease the excretion rate of Tropisetron which could result in a higher serum level.
AcebutololAcebutolol may increase the arrhythmogenic activities of Tropisetron.
AceclofenacAceclofenac may decrease the excretion rate of Tropisetron which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Tropisetron which could result in a higher serum level.
AcenocoumarolThe risk or severity of adverse effects can be increased when Tropisetron is combined with Acenocoumarol.
AcetaminophenAcetaminophen may decrease the excretion rate of Tropisetron which could result in a higher serum level.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Tropisetron.
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Tropisetron.
AcetyldigitoxinAcetyldigitoxin may increase the arrhythmogenic activities of Tropisetron.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Tropisetron which could result in a higher serum level.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Product Ingredients
IngredientUNIICASInChI Key
Tropisetron HydrochlorideA19338Q2YO105826-92-4XIEGSJAEZIGKSA-LUNMCBQDSA-N
Tropisetron MesylateX2V6FDY03T833482-77-2FFTYLXTULVZQRZ-LUNMCBQDSA-N

Categories

ATC Codes
A04AA03 — Tropisetron
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as indolecarboxylic acids and derivatives. These are compounds containing a carboxylic acid group (or a derivative thereof) linked to an indole.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Indolecarboxylic acids and derivatives
Direct Parent
Indolecarboxylic acids and derivatives
Alternative Parents
Tropane alkaloids / Indoles / Pyrrole carboxylic acids and derivatives / Benzenoids / Substituted pyrroles / Piperidines / N-alkylpyrrolidines / Vinylogous amides / Heteroaromatic compounds / Trialkylamines
show 8 more
Substituents
Amine / Amino acid or derivatives / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Carboxylic acid derivative / Carboxylic acid ester / Heteroaromatic compound / Hydrocarbon derivative / Indole
show 18 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
tertiary amino compound, azabicycloalkane, indolyl carboxylate ester (CHEBI:32269)

Chemical Identifiers

UNII
6I819NIK1W
CAS number
89565-68-4
InChI Key
ZNRGQMMCGHDTEI-ITGUQSILSA-N
InChI
InChI=1S/C17H20N2O2/c1-19-11-6-7-12(19)9-13(8-11)21-17(20)15-10-18-16-5-3-2-4-14(15)16/h2-5,10-13,18H,6-9H2,1H3/t11-,12+,13+
IUPAC Name
(1R,3R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 1H-indole-3-carboxylate
SMILES
[H][C@]12CC[C@]([H])(C[C@@]([H])(C1)OC(=O)C1=CNC3=CC=CC=C13)N2C

References

General References
  1. product info [Link]
  2. Monograph [Link]
  3. MSDS [Link]
  4. Article [Link]
  5. TITCK Product Information: Navoban (tropisetron) for oral use [Link]
  6. TITCK Product Information: Navoban (tropisetron) for intravenous injection [Link]
KEGG Compound
C13666
PubChem Compound
656665
PubChem Substance
347828064
ChemSpider
16736476
BindingDB
50108392
RxNav
27392
ChEBI
32269
ChEMBL
CHEMBL56564
ZINC
ZINC000100019233
PDBe Ligand
TKT
Wikipedia
Tropisetron
PDB Entries
2wnc / 5oaj / 6his

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentNausea / Vomiting1
4CompletedTreatmentPain1
4RecruitingOtherPostoperative Cognitive Dysfunction / Postoperative Delirium1
4RecruitingPreventionEmergence Delirium / Postoperative Delirium1
4RecruitingSupportive CareChemotherapy-Induced Nausea and Vomiting (CINV)1
4Unknown StatusTreatmentVomiting1
3CompletedTreatmentCessation, Smoking / Schizophrenia1
3Unknown StatusSupportive CareChemotherapy-Induced Nausea and Vomiting (CINV) / Colorectal Cancers1
2CompletedSupportive CareNausea and vomiting / Unspecified Adult Solid Tumor, Protocol Specific1
2CompletedTreatmentDisease, Chronic / Pain1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solution
InjectionIntravenous
Injection, solutionOral
Injection, solutionSubcutaneous
Injection, solutionIntravenous2 MG/2ML
SolutionIntravenous; Oral
CapsuleOral
Injection, solutionIntravenous
CapsuleOral5 mg
Injection, solutionIntravenous5 MG/5ML
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.33 mg/mLALOGPS
logP3.14ALOGPS
logP2.63ChemAxon
logS-2.3ALOGPS
pKa (Strongest Acidic)12.18ChemAxon
pKa (Strongest Basic)9.34ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area45.33 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity81.5 m3·mol-1ChemAxon
Polarizability31.35 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Drugtargets
Accelerate your drug discovery research
with our fully connected ADMET & drug target dataset.
Learn more
Accelerate your drug discovery research with our ADMET & drug target dataset
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Voltage-gated potassium channel activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gate...
Gene Name
HTR3A
Uniprot ID
P46098
Uniprot Name
5-hydroxytryptamine receptor 3A
Molecular Weight
55279.835 Da

Drug created on October 20, 2016 20:40 / Updated on February 21, 2021 18:53